ImmunoPhotonics
ImmunoPhotonics is a privately held, clinical-stage biotech developing IP-001, a proprietary glycan polymer immunotherapy injected after tumor ablation to convert local procedures into systemic cancer immunotherapy, targeting multiple solid tumor indications.
- Company typePrivate
- Founded2011
- HeadquartersSt Louis, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What ImmunoPhotonics does
ImmunoPhotonics is a privately held, clinical-stage biotechnology company pioneering a therapeutic category it has trademarked as Interventional Immuno-Oncology (IIO). The company's lead and only disclosed product is IP-001 (also referenced as inCVAX), a proprietary cationic glycan polymer designed to be injected at the site of routine tumor ablation procedures (RFA, MWA, cryoablation) or radiation. IP-001 functions as both an antigen depot—capturing tumor antigens liberated during ablation—and an immune activator that recruits antigen-presenting cells, engages the cGAS-STING innate immune pathway, and drives downstream T-cell activation while downregulating T-cell exhaustion. The intent is to convert a local, mechanical tumor-destruction procedure into a systemic immunotherapy capable of reaching distant metastases.
The company targets six solid tumor indications: colorectal cancer (CRC), non-small cell lung cancer (NSCLC), melanoma, soft tissue sarcoma (STS), hepatocellular carcinoma (HCC), and pancreatic cancer. It has completed the SAKK 66/17 Phase 1b/2a trial in collaboration with the Swiss Cancer Institute and the INJECTABL-1 Phase 1b/2a trial across the US, UK, France, Germany, and Switzerland, treating more than 120 patients cumulatively. A pivotal INJECTABL-3 Phase 2/3 trial is being conducted in partnership with CIRSE. IP-001 is also being explored as a vaccine adjuvant for infectious diseases, extending the platform's vertical scope beyond oncology.
The business model is currently pre-revenue. ImmunoPhotonics has no commercial product sales and no disclosed pricing; IP-001 is administered exclusively through clinical trials. Revenue mechanics are not yet established but are expected to flow through traditional pharmaceutical distribution channels, specialty pharmacies, and potentially licensing or co-development partnerships for global commercialization upon regulatory approval. The company has raised approximately $31.8 million in equity and grant financing since 2010, including a $21.4 million round in April 2022. Operations are based in St. Louis, Missouri (headquarters) and Bern, Switzerland (subsidiary IPS Biopharma AG), with patent coverage in over 40 countries and European exclusivity extending into 2039.
ImmunoPhotonics firmographics
Firmographics- Name
- ImmunoPhotonics
- Legal name
- Immunophotonics, Inc.
- Website
- https://immunophotonics.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- ImmunoPhotonics is a privately held, clinical-stage biotech developing IP-001, a proprietary glycan polymer immunotherapy injected after tumor ablation to convert local procedures into systemic cancer immunotherapy, targeting multiple solid tumor indications.
- Ownership category
- akta.pro rank
ImmunoPhotonics industry classification
Industry- Product category
- Cancer Immunotherapy / Interventional Immuno-Oncology
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro industry
- Therapeutic Vaccines (cancer, chronic infection immunotherapy)Dendritic Cell & Other APC-based TherapiesCytokines, Interferons & Immunomodulatory ProteinsHealthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)Immunology & Autoimmune Specialty Pharmaceuticals
Keywords
Where ImmunoPhotonics is headquartered
LocationHeadquarters
- HQ city
- St Louis
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
ImmunoPhotonics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Others, Marketing or Sales
Revenue model
- Pharmaceutical/ Biopharmaceutical Sales (Future): As a clinical-stage biotech company, Immunophotonics currently has no revenue. The company is developing IP-001 for cancer treatment, which if approved would be commercialized through traditional pharmaceutical distribution channels. The company may pursue licensing agreements or co-development partnerships for global commercialization.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
ImmunoPhotonics product offering
Product offeringCore offering
ImmunoPhotonics is a clinical-stage biopharmaceutical company developing IP-001 (inCVAX), a proprietary cationic glycan polymer immunotherapy administered as an intratumoral injection following routine tumor ablation (RFA, MWA, cryoablation) or radiation. IP-001 captures tumor antigens released during ablation and activates innate and adaptive immunity via the cGAS-STING pathway, transforming local procedures into systemic cancer immunotherapy across multiple solid tumor indications.
Product overview
Immunophotonics is a clinical-stage biotech company pioneering the field of Interventional Immuno-Oncology® with a single lead product, IP-001 (also referred to as inCVAX). IP-001 is a proprietary glycan polymer designed to stimulate the immune system by acting as an antigen depot and immune activator. The product is injected following routine tumor ablation procedures (such as RFA, MWA, or cryoablation) to capture tumor antigens released during ablation and activate antigen-presenting cells, thereby transforming local tumor destruction into a systemically active cancer immunotherapy. The company is also exploring IP-001 as a vaccine adjuvant for infectious diseases. The technology platform supports expansion into multiple solid tumor indications including colorectal cancer, NSCLC, melanoma, soft tissue sarcoma, hepatocellular carcinoma, and pancreatic cancer.
Differentiator
Problem solved
Functional benefit
Products and services
- IP-001 (inCVAX) Proprietary cationic glycan polymer administered as an intratumoral injection following standard tumor ablation (RFA, MWA, cryoablation) or radiation. Acts as an antigen depot and immune activator that captures liberated tumor antigens and stimulates innate and adaptive immunity via the cGAS-STING and inflammasome pathways, upregulating T-cell activation and downregulating T-cell exhaustion. Investigational; intended for solid tumor indications (colorectal, NSCLC, melanoma, soft tissue sarcoma, hepatocellular, pancreatic) with additional exploration as a vaccine adjuvant for infectious diseases.
Quantifiable outcome
- IP-001 has been tested in over 120 patients across multiple solid tumor indications
- +3 more outcomes
Companies that use ImmunoPhotonics
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
ImmunoPhotonics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
ImmunoPhotonics partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- CIRSE (Cardiovascular and Interventional Radiological Society of Europe)corePartnership for INJECTABL-3 Phase 2/3 clinical trial. CIRSE is a leading organization in interventional radiology, providing clinical trial support and physician network access for the innovative trial combining IP-001 with ablation procedures.
- Next ResearchminorClinical research organization partner for INJECTABL-3 Phase 2/3 clinical trial, providing operational support for the innovative interventional immuno-oncology study.
- Clinical Laserthermia Systems (CLS)coreResearch collaboration combining Immunophotonics' proprietary drug IP-001 with CLS's TRANBERG Laser Thermal Therapy System and imILT Method for cancer treatment. The collaboration supports Phase 1b/2a clinical trials combining IP-001 injection with laser ablation for solid tumor treatment.
- Swiss Cancer InstitutecoreCollaboration on SAKK 66/17 Phase 1b/2a multicenter clinical trial for treatment of solid tumors. Trial completed in 2025, evaluating IP-001 injection following thermal ablation in patients with advanced solid tumors including melanoma and soft tissue sarcoma.
- IPS Biopharma AG (Subsidiary)coreSwiss subsidiary headquartered in Bern, Switzerland, managing international business development, European clinical operations, and partnerships for Immunophotonics.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
ImmunoPhotonics competitors and assessment
Company assessmentEmerging players
- Compugen: Compugen uses computational biology to discover novel immuno-oncology targets, with COM701 (anti-PVRIG) in clinical development for solid tumors. It represents an emerging-platform competitor in the IO combination space.
- Galectin Therapeutics: Galectin develops galectin-3 inhibitors that modulate the tumor immune microenvironment and have shown activity in combination with checkpoint inhibitors. The platform approach of reprogramming immune response in solid tumors is similar in spirit to IP-001's mechanism.
- Werewolf Therapeutics: Werewolf develops tumor-activated immunotherapies (PREDATOR platform) that are designed to be activated selectively in the tumor microenvironment, sharing with IP-001 the goal of localizing immune activation at the tumor site while minimizing systemic toxicity.
Broad incumbents
- BioNTech: BioNTech's mRNA cancer vaccine pipeline (BNT122, individualized neoantigen therapies) and FixVac platform target similar solid tumor indications and use immune activation approaches. While BioNTech is a much larger incumbent, both companies are racing to develop antigen-driven cancer immunotherapies.
- Moderna: Moderna's oncology mRNA programs (mRNA-4157/V940 individualized neoantigen therapy, checkpoint inhibitor combinations) directly compete in the personalized cancer vaccine space. Moderna's resources, manufacturing scale, and melanoma Phase 2b readout against Merck's Keytruda represent the most formidable competitive threat in the field.
Direct peers
- Nektar Therapeutics: Nektar developed novel cytokine-based immunotherapies (bempegaldesleukin) and agonistic antibodies designed to enhance T-cell activation in the tumor microenvironment. Its IL-10 and T-cell engagers are mechanistically aligned with IP-001's approach of boosting cytotoxic T-cell responses.
- Iovance Biotherapeutics: Iovance develops autologous cell therapies (TIL) for solid tumors, directly competing for the same patient populations ImmunoPhotonics targets (melanoma, NSCLC, CRC). Both companies are in the post-ablation/standard-of-care solid tumor immunotherapy space with clinical-stage assets and large market opportunities.
- ImmunityBio: ImmunityBio develops IL-15-based immunotherapies (ANKTIVA) and NK cell therapies for solid tumors. The company's focus on T-cell and NK-cell activation in combination with checkpoint inhibitors is mechanistically aligned with IP-001's Th-1 and cytotoxic T-cell activation profile.
- OncoSec Medical (now Via Bio): OncoSec is a direct peer developing intratumoral immunotherapies (TAVO) that combine with tumor ablation/electroporation to generate systemic immune responses. Robert H. Arch, current President of ImmunoPhotonics, previously led strategy at OncoSec with TAVO-EP and FDA engagement, making the platforms and approaches highly comparable.
Others
- Clinical Laserthermia Systems (CLS): CLS is an existing co-development partner of ImmunoPhotonics, providing the TRANBERG laser ablation system used in the INJECTABL trials. As a strategic collaborator in the IIO combination workflow, CLS is an adjacent ecosystem participant enabling IP-001's clinical development.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
ImmunoPhotonics social profiles
Digital presenceImmunoPhotonics financial estimates
Financial estimateRevenue estimate
Valuation estimate
ImmunoPhotonics leadership team
Management profileNumber of profiles
Profiles11 records
ImmunoPhotonics subsidiaries and ownership
Company hierarchySubsidiaries1 record
ImmunoPhotonics funding detail
Funding detailFunding overview
Funding rounds11 records
Investors13 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ImmunoPhotonics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ImmunoPhotonics
What does ImmunoPhotonics do?
ImmunoPhotonics is a clinical-stage biopharmaceutical company developing IP-001 (inCVAX), a proprietary cationic glycan polymer immunotherapy administered as an intratumoral injection following routine tumor ablation (RFA, MWA, cryoablation) or radiation. IP-001 captures tumor antigens released during ablation and activates innate and adaptive immunity via the cGAS-STING pathway, transforming local procedures into systemic cancer immunotherapy across multiple solid tumor indications.
Is ImmunoPhotonics a public or private company?
ImmunoPhotonics is a private company. It is classified as venture growth investor backed and is currently operating.
When was ImmunoPhotonics founded?
ImmunoPhotonics was founded in 2011. It employs 11 to 50 people.
Where is ImmunoPhotonics based?
ImmunoPhotonics is headquartered in St Louis, United States, in the North America region.
How does ImmunoPhotonics make money?
One revenue line is on record: pharmaceutical/ Biopharmaceutical Sales (Future).
Who are ImmunoPhotonics's main competitors?
Emerging players on record are Compugen, Galectin Therapeutics and Werewolf Therapeutics. Broad incumbents are BioNTech and Moderna. Direct peers are Nektar Therapeutics, Iovance Biotherapeutics, ImmunityBio and OncoSec Medical (now Via Bio). Clinical Laserthermia Systems (CLS) is listed as an others.
Does ImmunoPhotonics have an API?
No public API is recorded for ImmunoPhotonics.
What industry is ImmunoPhotonics in?
ImmunoPhotonics's product category is Cancer Immunotherapy / Interventional Immuno-Oncology. Its primary akta.pro industry code is HLAAAEAB, Therapeutic Vaccines (cancer, chronic infection immunotherapy), with a secondary code of HLAAABAF, Dendritic Cell & Other APC-based Therapies. Its NAICS code is 325414 and its SIC code is 2834.